BPC-157 went mainstream, but the peptide conversation has moved on. Epithalon, thymalin, and skin/metabolism complexes are now being discussed by longevity physicians. Here's what each does and what the evidence actually supports.
When Bryan Johnson added peptides to the Immortals Rx platform, he wasn't talking primarily about BPC-157. The peptide conversation has moved significantly in 2026: tissue repair peptides like BPC-157 and TB-500 are now mainstream biohacking. The frontier discussion is about aging-specific peptides — compounds that target the thymus, telomere dynamics, and the fundamental rate of cellular aging rather than injury recovery.
Here is a clear overview of the most discussed longevity peptides in 2026, the evidence behind each, and how accessible they actually are.
Peptides are short amino acid chains that act as signaling molecules. The body uses thousands of peptides to regulate virtually every physiological process: hormone secretion, immune modulation, tissue growth, metabolism, and more. Synthetic peptide drugs mimic or amplify these endogenous signals.
The longevity appeal is mechanistic precision: rather than broad pharmacological effects (like most drugs), peptides aim to restore specific signaling pathways that decline with age. The thymus involutes (shrinks) after puberty; immune peptides aim to partially reverse that involution. Telomeres shorten with each cell division; telomerase-activating peptides theoretically slow that process. Cellular senescence accelerates with age; peptides that target senescent cell accumulation are under investigation.
The caveat is that peptide research is largely early-stage. Much of it originates from Soviet and Eastern European research programs in the 1970s–90s (particularly thymic and pineal peptides) where clinical standards differ from modern Western RCT requirements.